QN
QNRX.US Quoin Pharmaceuticals Ltd DRC
- Market cap
- USD 17.1M
- P/E
- 8.1x
- P/B
- 0.60x
- ROE
- -71.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is QNRX.US undervalued?
Graham numberQNRX.US trades 53.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Quoin Pharmaceuticals Ltd DRC fundamental analysis
No fundamental analysis for Quoin Pharmaceuticals Ltd DRC yet.
Quoin Pharmaceuticals Ltd DRC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, whic…
Full company profileQuoin Pharmaceuticals Ltd DRC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Quoin Pharmaceuticals Ltd DRC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | -280K | - | -280K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -280K | -104K | -280K | -227K | -105K | -104K | -104K | -103K | -100K | -101K | - |
| Operating Income | 15.3M | 10.2M | 15.3M | -1.56M | -1.67M | -6.06M | -9.26M | -9.38M | -9.53M | -16.3M | -20.8M |
| EBITDA | 15.3M | 10.2M | 15.3M | -1.54M | -1.57M | -20.3M | -8.56M | -8.58M | -8.86M | -15.7M | -20.7M |
| Net Income | 15.3M | 10.2M | 15.3M | -1.56M | -2.10M | -21.5M | -9.38M | -8.69M | -8.96M | -15.8M | -20.4M |
| EPS | 353,170 | 190,808 | 248,532 | -15,410 | -3,663 | -13,439 | -813 | -337 | -67 | -11 | -4.05 |
| Balance Sheet | |||||||||||
| Total Assets | 8.81M | 8.75M | 5.52M | 6.17M | 1.38M | 9.36M | 14.5M | 12.2M | 15.7M | 20.4M | 34.7M |
| Total Liabilities | 1.41M | 3.32M | 1.80M | 1.88M | 7.99M | 8.70M | 7.05M | 6.51M | 6.50M | 7.27M | 6.05M |
| Shareholders' Equity | 7.40M | 5.43M | 3.73M | 4.30M | -6.61M | 657K | 7.41M | 5.66M | 9.20M | 13.1M | 28.7M |
| Cash & Short-term Investments | 8.04M | 7.99M | 4.77M | 5.24M | 324K | 7.48M | 12.9M | 10.7M | 14.1M | 3.82B | 10.1M |
| Total Debt | 15.1K | - | - | 311K | 1.21M | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.77M | -4.98M | -6.57M | -5.71M | -1.34M | -5.72M | -8.48M | -7.86M | -7.86M | -13.5M | -18.5M |
| Capital Expenditure | 331K | 74.5K | 182K | 34.5K | 125K | 625K | 250K | 3.77 | 0.00 | 4.00 | 4.00 |
| Free Cash Flow | -4.10M | -5.05M | -6.76M | -5.74M | -1.46M | -6.35M | -8.73M | -7.86M | -7.86M | -13.5M | -18.5M |
| Ratios | |||||||||||
| ROE | 206.9% | 187.3% | 411.1% | -36.3% | - | -3,266.6% | -126.7% | -153.4% | -97.4% | -120.5% | -71.2% |
| ROA | 173.8% | 116.3% | 277.3% | -25.3% | -152.1% | -229.4% | -64.9% | -71.4% | -57.1% | -77.5% | -58.8% |
| Debt to Equity | 0.00x | - | - | 0.07x | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Quoin Pharmaceuticals Ltd DRC dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 65.3M | 5,656 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:35 on Apr 9, 2025.
Who owns Quoin Pharmaceuticals Ltd DRC
- Insiders 3.67%
- Institutions 55.40%
- Public & others 40.93%
- Shares outstanding 4.80M
- Free float 4.38M
Top funds holding QNRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Abante Quant Value FI | 10.5K | 0.22% | 0.00% | Aug 2026 |
Top institutions holding QNRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Dauntless Investment Group, LLC | 215K | 4.48% | +9.36% | Jun 2026 |
| Ikarian Capital, LLC | 212K | 4.40% | 0.00% | Jun 2026 |
| Stonepine Capital Management Llc | 199K | 4.15% | +273.15% | Jun 2026 |
| Millennium Management LLC | 112K | 2.34% | +47.31% | Jun 2026 |
| SummitTX Capital, L.P | 100K | 2.09% | 0.00% | Jun 2026 |
| Woodline Partners LP | 76.4K | 1.59% | -3.94% | Jun 2026 |
| Soleus Capital Management, L.P. | 72.7K | 1.51% | 0.00% | Jun 2026 |
| AIGH Capital Management, LLC | 70.0K | 1.46% | +37.25% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 59.8K | 1.25% | 0.00% | Jun 2026 |
| Velan Capital Investment Management LP | 32.4K | 0.67% | -61.85% | Jun 2026 |
| Barclays PLC | 21.5K | 0.45% | +1,551.46% | Jun 2026 |
| Birchview Capital, LP | 20.0K | 0.42% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 15.0K | 0.31% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 8.00K | 0.17% | +100.00% | Jun 2026 |
| UBS Group AG | 6.77K | 0.14% | +169.59% | Jun 2026 |
| Rhumbline Advisers | 3.17K | 0.07% | +35.89% | Sep 2026 |
| GAMMA Investing LLC | 439.00 | 0.01% | -74.48% | Jun 2026 |
| SBI Securities Co Ltd | 355.00 | 0.01% | +17,650.00% | Jun 2026 |
| Centiva Capital LP | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Citadel Advisors Llc | 0.00 | 0.00% | -100.00% | Jun 2026 |
Quoin Pharmaceuticals Ltd DRC company profile
- Company name
- Quoin Pharmaceuticals Ltd DRC
- Ticker
- QNRX.US
- Exchange
- USA Stocks
- Listed since
- Jul 29, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- December
- Address
- 42127 Pleasant Forest Court, Ashburn, VA, United States, 20148-7349
- Phone
- 703 980 4182
- Website
- quoinpharma.com
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Quoin Pharmaceuticals Ltd DRC management
3- Dr. Michael Myers Ph.D.Co-Founder, CEO & Chairman · born 1962
- Ms. Denise CarterCo-Founder, COO & Director · born 1969
- Ms. Sally LawlorChief Financial Officer · born 1983